Sun Pharma Commits MFN Pricing to US Government, Securing Two-Year Tariff Delay
Sun Pharmaceutical Industries Limited (Sun Pharma) and its affiliated companies announced agreements with the U.S. government at a White House ceremony, focusing on improving access to medicines for American patients.Sun Pharma committed to implementing Most Favored Nation (MFN) pricing for state Medicaid programs. The company also pledged MFN pricing for all future innovative medicine launches. In recognition of Sun Pharma’s investment in the U.S. market, the agreements include delaying Section 232 tariffs on innovative pharmaceutical products for over two years.
"Our mission is to reach people and touch lives by providing quality medicines across a patient's entire treatment journey, from consumer health products to generics to innovative medicines," said Rick Ascroft, North America CEO of Sun Pharma. Ascroft noted that the United States is a critical area of investment and expansion for the company, spanning clinical development, sales and marketing, and the manufacturing of both Active Pharmaceutical Ingredients (API) and finished products.
The U.S. represents Sun Pharma's largest market for innovative medicines and forms a cornerstone of its long-term growth strategy, contributing approximately 27% of the company’s global revenue.
Sun Pharma built its U.S. presence starting with high-quality generics, which has been complemented by a focus on innovative and specialty medicines. The company currently ranks second by prescriptions in U.S. dermatology and is actively expanding its presence across dermatology, immunology, cutaneous oncology, and ophthalmology.
The company’s portfolio includes a robust consumer health products and generics business. Sun Pharma’s global Innovative Medicines portfolio accounts for about 22% of company sales, covering products in dermatology, ophthalmology, and oncodermatology.
The company’s commitment to the U.S. market was previously highlighted by the definitive agreement to acquire Organon & Co. at an enterprise value of $11.75 billion. Sun Pharma continues to focus on its mission of expanding access to high-quality, affordable medicines globally.
SUNPHARMA Stock Price Movement
Sun Pharmaceutical Industries Limited rallied on Monday, closing at ₹1984.80 after gaining 3.38% from the previous close. The stock was traded with a volume of 2.41 million shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.